CTLA4 and neoplasm: ICIs, particularly those targeting the PD-1/PD-L1 and CTLA-4 pathways, have demonstrated substantial clinical benefit across a range of malignancies in the general population, particularly in tumors characterized by high mutation burden and pre-existing anti-tumor immunity.